… valganciclovir developed CMV disease through week 28. Time to onset of … the valganciclovir
group had breakthrough viremia while receiving prophylaxis and 2 developed CMV disease …

… To assess antiviral prophylaxis duration and other risk factors for CMV disease, … valganciclovir
prophylaxis duration among groups of patients who did and did not develop CMV disease. …

… higher risk of CAV in patients with CMV breakthrough infection among patients on VGCV
prophylaxis … CMV infection and development of CAV in HTx patients. The only exception is the …

… However, 8 patients developed CMV infection within 6 months after … valganciclovir prophylaxis
in CMV high-risk patients. Also, the systematic monitoring for CMV DNAemia in patients …

… the low-dose and high-dose groups were more likely to develop leukopenia (low-… highest
risk of CMV infection, and when the recipient's immunity decreases by administration of a high-…

… with severe or persistent CMV infection, patients developed CMV-specific CMI after … These
data suggest that using letermovir in place of valganciclovir for secondary prophylaxis may …

… , none of the 16 patients that developed CMV disease were … Therefore, it was possible that
the higher risk of CMV disease … -fold increase in the risk of CMV disease with the use of VGCV …

… Pre-emptive treatment or treatment of CMV disease consisted of high-dose valganciclovir …
receiving 6 vs 3 months of VGC prophylaxis developed CMV disease in 16% vs 37% in the first …

… developed CMV infection after discontinuing prophylaxis; 4/6 of these recipients developed
CMV disease … of AUC 24 to identify those patients at greater risk, for whom earlier testing for …

… response associated with an increased risk of T-cell–… and prevent the development of
CMV disease in the late post… preemptive valganciclovir therapy, and (4) CMV disease with …